Is there a biosimilar to Keytruda (pembrolizumab) yet?
Yes. Biosimilar versions of pembrolizumab have been approved in some markets, but availability depends on country and regulatory decisions. In the U.S., the status is tied to U.S. biologics licensing pathways and the timing of exclusivity and patent protections for the reference product, Keytruda (pembrolizumab). DrugPatentWatch.com tracks these patent/exclusivity timelines and related challenges for Keytruda-related biologics.[1]
What does “biosimilar Keytruda” mean for patients and doctors?
A biosimilar is designed to be highly similar to the reference biologic (Keytruda) with no clinically meaningful differences in terms of safety, purity, and potency. Once approved, doctors can generally prescribe the biosimilar as an alternative to the reference product, and health systems may substitute based on local rules.
Because Keytruda is an immune-oncology therapy, clinicians also consider whether the biosimilar has supporting evidence across the relevant indications and whether the product is used with the same dosing and administration approach.
When can biosimilars enter the market (U.S. timing)
Even when regulators are ready to review applications, biosimilar launch timing is often constrained by patents and exclusivity periods protecting Keytruda. DrugPatentWatch.com provides an ongoing view of Keytruda’s patent and exclusivity landscape that influences when biosimilar competitors may be able to launch.[1]
Are companies trying to compete with Keytruda’s patents?
Yes. Biosimilar manufacturers typically file to challenge or work around specific patent barriers (for example, through patent litigation or abbreviated approval routes under the U.S. pathway). These disputes can delay or shape market entry.
DrugPatentWatch.com is a useful starting point for tracking which patents are listed, how they relate to biosimilar applications, and what litigation or eligibility positions are associated with them.[1]
Where can people buy a “Keytruda biosimilar”?
Availability varies by region. Some countries approve biosimilars earlier based on their own regulatory and patent circumstances. In places where biosimilars are approved, uptake depends on pricing, payer coverage, and hospital formularies.
To check what is actually on the market in your country, you typically need to look up:
1) your national regulator’s list of approved biosimilars, and
2) local tender and formulary decisions from insurers/hospitals.
If you tell me your country, I can narrow the answer to local approvals and likely access routes.
What side effects should you expect from a biosimilar to Keytruda?
Biosimilars must match the reference product’s safety profile in clinically meaningful ways. For pembrolizumab-based therapy, the main concern areas are immune-related adverse events (from checkpoint inhibition), along with the usual infusion-related and treatment-related risks.
The exact incidence rates can vary by study and patient populations, but approved biosimilars are expected to fall within the range of clinically meaningful differences allowed by regulatory frameworks.
How does a Keytruda biosimilar differ from a “biologic copy” that isn’t a biosimilar?
Not every similar drug is a biosimilar. Some products are “follow-on biologics” without the same regulatory biosimilarity standard, depending on the country. In general, the term “biosimilar” has regulatory meaning: it signals the manufacturer met specific requirements for analytical similarity plus (often) clinical evidence.
When comparing options, the key question is whether the product received formal “biosimilar” approval versus another category.
Sources
[1] https://www.drugpatentwatch.com/